ReviewOncoTargets and therapy2022
Targeting
Review in OncoTargets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer.bioRxiv : the preprint server for biology · 2026Article
- Enhanced Killing of Colon Cancer Cells by Mesoporous Silica Nanoparticles Loaded with Ellagic Acid.Nanomaterials (Basel, Switzerland) · 2025Article
- Appendiceal mucinous neoplasms: Optimizing treatment strategies based on clinical, histological, and molecular features.World journal of clinical oncology · 2025Review
- Adagrasib in the treatment of colorectal cancer.Future oncology (London, England) · 2025Review
- Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.Investigational new drugs · 2025Review
- KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy.Cancers · 2025Review
- Article
- Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.Cancer discovery · 2024Article
- From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer.Current treatment options in oncology · 2024Review
- Integrated molecular profiling ofJournal of gastrointestinal oncology · 2024Article
- The effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Review
- Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status.Investigational new drugs · 2024Article
- Precision medicine in metastatic colorectal cancer: targetingTranslational gastroenterology and hepatology · 2024Article
- Assessment of KRASFrontiers in oncology · 2024Review
- Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.International journal of molecular sciences · 2023Review
- Pharmacogenomics: Driving Personalized Medicine.Pharmacological reviews · 2023Review
- Irinotecan- vs. Oxaliplatin-Based Doublets in KRASCancers · 2023Article
- Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.Frontiers in oncology · 2023Review
- Evaluation of AMG510 Therapy onBioengineering (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.